Arfolitixorin - a drug candidate
for treatment of colorectal cancer

Read more >>

See how arfolitixorin
works in cancer cells

See the animation >>

The global Phase III AGENT study

The AGENT study with arfolitixorin

is ongoing at more than 80 hospitals

in The US, Canada, Europe, Australia and Japan

Read More >>

Previous

Next

Startpage 2

Upcoming Events

  • May 05, 2020 - May 05, 2020
    Extra Ordinary General Meeting
  • May 14, 2020 - May 14, 2020
    Intermin Report Q1 2020
  • May 14, 2020 - May 14, 2020
    Annual General Meeting 2020
  • August 21, 2020 - August 21, 2020
    Intermin Report Q2 2020